Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wellstat Therapeutics has sold uridine triacetate's commercialization rights to BTG, a developer and commercializer of products targeting critical care, cancer and other disorders.
Subscribe to our email newsletter
Wellstat’s uridine triacetate is indicated as a treatment for accidental exposure to the chemotherapeutic 5-fluorouracil (5-FU).
The agreement allows BTG to mark, sell and distribute uridine triacetate in the US for 10 years following marketing approval.
However, Wellstat will be responsible to manufacture the drug and to complete development and regulatory filing for the product.
As per the terms of the agreement, Wellstat is eligible to get a sum of $7.5m from BTG as well as milestone payments upon NDA acceptance and approval and transfer pricing payments based on manufacturing costs and a significant percentage of net sales.
The company plans to submit new drug application (NDA) during the first half of 2013.
Wellstat Licensing and Business Development vice president David Wohlstadter said they believe their investigational antidote has potential to be a safe and effective therapy in overexposure to 5-FU, and that their agreement with BTG further validates the strength and depth of Wellstat’s drug discovery, research and development capabilities.